Transforming growth factor‑β/miR‑143‑3p/cystatin B axis is a therapeutic target in human ovarian cancer

Guan,Wencai; Wang,Xingxing; Lin,Qunbo; Zhang,Jinguo; Ren,Weimin; Xu,Guoxiong

doi:10.3892/ijo.2019.4815

Transforming growth factor‑β/miR‑143‑3p/cystatin B axis is a therapeutic target in human ovarian cancer

Authors:
- Wencai Guan
- Xingxing Wang
- Qunbo Lin
- Jinguo Zhang
- Weimin Ren
- Guoxiong Xu
View Affiliations

Affiliations: Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: May 28, 2019 https://doi.org/10.3892/ijo.2019.4815
Pages: 267-276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously reported that cystatin B (CSTB) is a progression marker of human ovarian cancer (OC); however, the regulatory mechanism of CSTB and its function in OC remain unclear. The present study aimed to explore the mechanism underlying transforming growth factor-β (TGF‑β) 1‑mediated CSTB regulation, and to examine the function of CSTB on OC cell proliferation and apoptosis. Using the online program, miRWalk, a microRNA (miR)‑143‑3p was detected, which contains a homologous sequence of the potential binding site to the 3'‑untranslated region (3'‑UTR) of CSTB. A dual‑luciferase reporter assay confirmed the interaction between miR‑143‑3p and CSTB 3'‑UTR. Treating OC cells with miR‑143‑3p mimics or inhibitors resulted in a decrease or an increase of CSTB expression at mRNA and protein levels, respectively. Additionally, CSTB was significantly overexpressed, whereas miR‑143‑3p was downregulated in human OC tissues compared with normal ovarian tissues. A negative correlation between miR‑143‑3p and CSTB mRNA expression was observed in ovarian malignant tumors. The levels of primary and mature miR‑143‑3p expression were upregulated in OC cells after TGF‑β1 treatment; the action of TGF‑β1 was abolished in the presence of an inhibitor of TGF‑β type I receptor. These results indicated an axis between TGF‑β, miR‑143‑3p and CSTB in OC cells. Furthermore, high levels of CSTB expression were associated with the poor overall survival of patients with OC. Knockdown of CSTB resulted in a decrease in OC cell proliferation and arrested cells in G2/M phase. In addition, suppression of CSTB induced cell apoptosis. In conclusion, CSTB was overexpressed and miR‑143‑3p was downregulated in ovarian malignant tumors. Mature miR‑143‑3p directly bound CSTB 3'‑UTR, leading to a decrease in CSTB expression in OC cells, which was regulated by TGF‑β1. Our findings suggest the potential therapeutic application of targeting the TGF‑β/miR‑143‑3p/CSTB axis for treating patients with OC.

View Figures

View References

1	Turk V, Stoka V and Turk D: Cystatins: Biochemical and structural properties, and medical relevance. Front Biosci. 13:5406–5420. 2008. View Article : Google Scholar : PubMed/NCBI
2	Žerovnik E: Putative alternative functions of human stefin B (cystatin B): Binding to amyloid-beta, membranes, and copper. J Mol Recognit. 30:302017. View Article : Google Scholar
3	Wang X, Gui L, Zhang Y, Zhang J, Shi J and Xu G: Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway. Int J Oncol. 44:1099–1106. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
5	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
6	Maher K, Jerič Kokelj B, Butinar M, Mikhaylov G, Manček-Keber M, Stoka V, Vasiljeva O, Turk B, Grigoryev SA and Kopitar-Jerala N: A role for stefin B (cystatin B) in inflammation and endotoxemia. J Biol Chem. 289:31736–31750. 2014. View Article : Google Scholar : PubMed/NCBI
7	Lalioti MD, Scott HS, Buresi C, Rossier C, Bottani A, Morris MA, Malafosse A and Antonarakis SE: Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature. 386:847–851. 1997. View Article : Google Scholar : PubMed/NCBI
8	Gashenko EA, Lebedeva VA, Brak IV, Tsykalenko EA, Vinokurova GV and Korolenko TA: Evaluation of serum proca-thepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer. Int J Circumpolar Health. 72:212152013. View Article : Google Scholar
9	Feldman AS, Banyard J, Wu CL, McDougal WS and Zetter BR: Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 15:1024–1031. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lee MJ, Yu GR, Park SH, Cho BH, Ahn JS, Park HJ, Song EY and Kim DG: Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin Cancer Res. 14:1080–1089. 2008. View Article : Google Scholar : PubMed/NCBI
11	Shiraishi T, Mori M, Tanaka S, Sugimachi K and Akiyoshi T: Identification of cystatin B in human esophageal carcinoma, using differential displays in which the gene expression is related to lymph-node metastasis. Int J Cancer. 79:175–178. 1998. View Article : Google Scholar : PubMed/NCBI
12	Treiber T, Treiber N and Meister G: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar
13	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
14	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
15	van Kouwenhove M, Kedde M and Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 11:644–656. 2011. View Article : Google Scholar
16	Zhang L, Nadeem L, Connor K and Xu G: Mechanisms and therapeutic targets of microRNA-associated chemoresistance in epithelial ovarian cancer. Curr Cancer Drug Targets. 16:429–441. 2016. View Article : Google Scholar : PubMed/NCBI
17	Behbahani GD, Ghahhari NM, Javidi MA, Molan AF, Feizi N and Babashah S: MicroRNA-mediated post-transcriptional regulation of epithelial to mesenchymal transition in cancer. Pathol Oncol Res. 23:1–12. 2017. View Article : Google Scholar
18	Schetter AJ, Heegaard NH and Harris CC: Inflammation and cancer: Interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010. View Article : Google Scholar
19	Ottley E and Gold E: microRNA and non-canonical TGF-β signalling: Implications for prostate cancer therapy. Crit Rev Oncol Hematol. 92:49–60. 2014. View Article : Google Scholar
20	Shi Y and Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar
21	Attisano L and Wrana JL: Signal transduction by the TGF-beta superfamily. Science. 296:1646–1647. 2002. View Article : Google Scholar
22	Schmierer B and Hill CS: TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 8:970–982. 2007. View Article : Google Scholar
23	Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
24	Sun W, Gui L, Zuo X, Zhang L, Zhou D, Duan X, Ren W and Xu G: Human epithelial-type ovarian tumour marker beta-2-micro-globulin is regulated by the TGF-β signaling pathway. J Transl Med. 14:752016. View Article : Google Scholar
25	Matsumoto T, Yokoi A, Hashimura M, Oguri Y, Akiya M and Saegusa M: TGF-β-mediated LEFTY/Akt/GSK-3β/Snail axis modulates epithelial-mesenchymal transition and cancer stem cell properties in ovarian clear cell carcinomas. Mol Carcinog. 57:957–967. 2018. View Article : Google Scholar : PubMed/NCBI
26	Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
27	Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, et al: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68:5478–5486. 2008. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) μethod. Methods. 25:402–408. 2001. View Article : Google Scholar
29	Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T and Naito Z: Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma. Int J Oncol. 46:1573–1581. 2015. View Article : Google Scholar : PubMed/NCBI
30	Lin YY, Chen ZW, Lin ZP, Lin LB, Yang XM, Xu LY and Xie Q: Tissue Levels of Stefin A and Stefin B in Hepatocellular Carcinoma. Anat Rec (Hoboken). 299:428–438. 2016. View Article : Google Scholar
31	Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brünner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: Relation to prognosis. Clin Cancer Res. 6:505–511. 2000.PubMed/NCBI
32	Butinar M, Prebanda MT, Rajkovic J, Jerič B, Stoka V, Peters C, Reinheckel T, Krüger A, Turk V, Turk B, et al: Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model. Oncogene. 33:3392–3400. 2014. View Article : Google Scholar
33	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
34	Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar
35	Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
36	He Z, Yi J, Liu X, Chen J, Han S, Jin L, Chen L and Song H: MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Mol Cancer. 15:512016. View Article : Google Scholar : PubMed/NCBI
37	Zhai L, Ma C, Li W, Yang S and Liu Z: miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5. Mol Carcinog. 55:1990–2000. 2016. View Article : Google Scholar
38	Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, Li P, Zhang W, Wu H, Feng N, et al: miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 350:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
39	Song T, Zhang X, Wang C, Wu Y, Dong J, Gao J, Cai W and Hong B: Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev. 12:929–933. 2011.
40	Shi H, Shen H, Xu J, Zhao S, Yao S and Jiang N: MiR-143-3p suppresses the progression of ovarian cancer. Am J Transl Res. 10:866–874. 2018.
41	Long X and Miano JM: Transforming growth factor-beta1 (TGF-beta1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem. 286:30119–30129. 2011. View Article : Google Scholar
42	Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G and Hata A: down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem. 286:28097–28110. 2011. View Article : Google Scholar : PubMed/NCBI